anti-CD5 mAbs chimeric (Symphogen)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD5 mAbs chimeric (Symphogen)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSymphogen A/S

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesSymphogen A/S

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A